Etanercept: therapeutic use in patients with rheumatoid arthritis - Wikidata - awgldk - TriplyDB

Etanercept: therapeutic use in patients with rheumatoid arthritis

Etanercept: therapeutic use in patients with rheumatoid arthritis

http://www.wikidata.org/entity/Q33782355

about

Anti-cytokine therapy in chronic destructive arthritis Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey Antidrug Antibodies: B Cell Immunity Against Therapy Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001)Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002).Lipid profiles alter from pro-atherogenic into less atherogenic and proinflammatory in juvenile idiopathic arthritis patients responding to anti TNF-α treatment.Autoantibodies against interleukin 1alpha in rheumatoid arthritis: association with long term radiographic outcome.Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005 Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.The safety of etanercept for the treatment of plaque psoriasis.Placenta suppresses experimental autoimmune hypophysitis through soluble TNF receptor 1 The discovery of novel protein kinase inhibitors by using fragment-based high-throughput x-ray crystallography.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 Effect of TNF antagonists on the productivity of daily work of patients with rheumatoid arthritis.The use of TNF-alpha blocking agents in rheumatoid arthritis: an update.Soluble T cell receptor Vβ domains engineered for high-affinity binding to staphylococcal or streptococcal superantigens Effects of dialkoxylphenyl compounds with oxime group on macrophage function and the proliferation of lymphocytes."Inverse wrap": an improved implantation technique for virus-transduced synovial fibroblasts in the SCID mouse model for rheumatoid arthritis.Tumor necrosis factor-alpha levels after surgical anti-infective mechanical therapy for peri-implantitis: a 12-month follow-up.Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy.Additional effect of etanercept or infliximab on the liver function tests of patients with rheumatoid arthritis: a cohort study

P2860

Q24805245-EBDD9CEF-6076-4279-91A6-980F345EF596 Q24816756-32976C9C-3CD7-4722-90D7-AD7341D88054 Q28082303-90264B3E-F71A-4421-A2F8-C71A3AD47B97 Q34560553-36729091-903D-437C-AD37-B686ACEA54E0 Q34962946-FDA25D58-46D9-48B0-9015-BC656342C3E1 Q35112757-6CF8C0A0-69A8-4CE8-A57A-1CB10A55BFCD Q35551774-AF13B610-2E5E-43DD-8860-233F972C6AE0 Q35553451-5435DCFE-CBC4-4255-AE72-043CAEF61E03 Q35579352-C4DADB0B-3F06-433B-8ACE-3811AF87BA89 Q35579517-12E26674-9200-4A37-B178-062E36B530D8 Q35638252-EBDA6BDD-CF1A-468D-8733-894351B0A01F Q35919214-6CA84B87-216D-46BA-A4FA-C4DE9CDF4879 Q36020169-CE6AC2A6-E11E-4DE8-972C-D3DB6787512D Q36033077-D22DE42F-3609-4EE4-B4D2-0FEF96904BCB Q36171750-9948F3CA-FE1D-4DBB-8223-7E784984E659 Q36555104-02ECF58A-5411-4437-90A5-4B302F83D071 Q36916918-175B30AF-C9B9-47A7-84E2-0B78339324C3 Q37617797-0808DA73-E2BC-47FE-AAE9-7F05B34EBA81 Q44852650-6FE747CE-16CE-4B03-BDE7-669CD43DBC0E Q45348363-D923FFC1-C1C6-49BD-ADB8-41C0BB8FD92D Q46067295-81E722C2-1AFA-4E62-B1CD-3B6379FBB7DD Q47629226-E21DF17D-307F-465B-ADE0-C2981BE9F6CF Q57817317-9C3E1913-3D5A-46B1-AF3C-1E66480DAEEC

P2860

Etanercept: therapeutic use in patients with rheumatoid arthritis

http://www.wikidata.org/entity/Q33782355

description

1999 nî lūn-bûn

@nan

1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

Etanercept: therapeutic use in patients with rheumatoid arthritis

@ast

Etanercept: therapeutic use in patients with rheumatoid arthritis

@en

type

label

Etanercept: therapeutic use in patients with rheumatoid arthritis

@ast

Etanercept: therapeutic use in patients with rheumatoid arthritis

@en

prefLabel

Etanercept: therapeutic use in patients with rheumatoid arthritis

@ast

Etanercept: therapeutic use in patients with rheumatoid arthritis

@en

P1433

Q33782355-A22B647F-BF2D-4594-80A7-EE341BB6AE04

P1476

Q33782355-A8016878-6D62-4A8A-B9EF-8171660E6D2E

P2093

Q33782355-BF7DCD51-48FC-4026-BA18-B7D2C13B5650

Q33782355-D2BD0BC3-DFF8-4A03-9EFC-B7D41CCEA216

P2860

Q33782355-0B83D164-0270-4E39-B6EC-50F06B441975

Q33782355-191FFC4E-9159-4D19-9D69-5C1E13F52866

Q33782355-2359C02C-2377-4E32-A303-004F9319ED01

Q33782355-294C8E05-BEA8-4469-A163-BF4CC4DABFF1

Q33782355-473CB6E5-986A-40D5-BE1A-1396AC3F6EAB

Q33782355-500414B7-F48B-4447-9E9F-9681AFE99794

Q33782355-691D9BF6-6F22-4408-ADA5-8887FF60F2EB

Q33782355-73742278-EFA3-4CA3-9248-7FA167690DFE

Q33782355-86ED7E8D-8194-424C-AAC3-4C332DFAE952

Q33782355-8A540C8B-D202-4CBA-B4AB-4C8A2C3273C4

P304

Q33782355-E356883F-C596-4311-9276-18971763FE67

P31

Q33782355-974F30D7-9419-4623-BA1E-1FAFF9268942

P356

Q33782355-4366793B-38DB-4885-BDAC-BE01A1AA51F4

P407

Q33782355-D76D6CBF-864B-4E1E-B34F-C54E02DD143B

P478

Q33782355-DC4255A5-AFA2-444F-AFF2-8361F3A0D2B4

P577

Q33782355-124537F0-D972-4A05-801F-F50E70ADF62B

P5875

Q33782355-DA6EC097-0BA8-4F3D-82A5-0E664C87BFDE

P698

Q33782355-7589EB0D-8B2E-4BF4-A8AF-50A8F5AE38CE

P932

Q33782355-24CD7E73-FE76-4DEA-A413-5206FE684F04

P356

ARD.58.2008.I65

P1433

Annals of the Rheumatic Diseases

P1476

Etanercept: therapeutic use in patients with rheumatoid arthritis

@en

P2093

Garrison L

http://www.w3.org/2001/XMLSchema#string

McDonnell ND

http://www.w3.org/2001/XMLSchema#string

P2860

Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis.

Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin.

Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts

Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1

Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo

Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies.

The tumor necrosis factor ligand and receptor families.

TNF inhibitors are produced spontaneously by rheumatoid and osteoarthritic synovial joint cell cultures: evidence of feedback control of TNF action.

P304

I65-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ARD.58.2008.I65

http://www.w3.org/2001/XMLSchema#string

P407

P478

58 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

1999-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12723229

http://www.w3.org/2001/XMLSchema#string

P698

10577976

http://www.w3.org/2001/XMLSchema#string

P932

1766576

http://www.w3.org/2001/XMLSchema#string